# The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

> **NCT03059069** · PHASE4 · RECRUITING · sponsor: **Yonsei University** · enrollment: 60 (estimated)

## Conditions studied

- Type2 Diabetes With Depressive Mood

## Interventions

- **DRUG:** Chonline Alphoscerate
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03059069
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-06-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03059069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03059069, "The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03059069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*